Brief: Windtree Therapeutics Announces KL4 Surfactant And Aerosurf Global License Agreement
23/08/2022 13:06
Aug 23 (Reuters) - Windtree Therapeutics Inc WINT.O :
* WINDTREE THERAPEUTICS ANNOUNCES KL4 SURFACTANT AND
AEROSURF®
GLOBAL LICENSE AGREEMENT
* WINDTREE THERAPEUTICS INC- MAY RECEIVE UP TO $78.9 MILLION
IN
DEVELOPMENT, REGULATORY AND COMMERCIAL MILESTONES PLUS LOW
DOUBLE DIGIT ROYALTIES
* WINDTREE THERAPEUTICS INC- DEVELOPMENT AND ALL OTHER COSTS
TO BE
ASSUMED BY LEE'S PHARMACEUTICAL AND ZHAOKE PHARMACEUTICAL
* WINDTREE THERAPEUTICS INC- ENTERED INTO GLOBAL LICENSING
AGREEMENT WITH LEE'S PHARMACEUTICAL (HK) LIMITED, AFFILIATE
ZHAOKE PHARMACEUTICAL (HEFEI) CO
* WINDTREE THERAPEUTICS INC- WILL NO LONGER HAVE ONGOING
MAINTENANCE AND OPERATING COSTS FOR KL4 PLATFORM
Source text for Eikon: ID:nGNX436XHy
Further company coverage: WINT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Windtree Therapeutics
See all newsBrief: Windtree Therapeutics Announces It Has Signed A Letter Of Intent To Acquire Commloan
Brief: Windtree Therapeutics Announces It May Receive License Agreement Payments From Its Licensee For Renewed Acute Pulmonary Development By The Licensee
Brief: Windtree Therapeutics Stockholders Approve Key Proposals For Revenue And Profit Generation At The Special Stockholder Meeting
Brief: Windtree Therapeutics Terminates Seismic-C Clinical Study At 20 Enrollments - SEC Filing
Brief: Windtree Therapeutics Inc - Announces Interim Analysis Of Istaroxime Phase 2 Study